VHL and nonpapillary renal cell carcinoma: The first-line treatment of metastatic ccRCC is the angiogenesis inhibitor sunitinib, a multi-tyrosine kinase inhibitor that reduces the effects deriving from several important pVHL- and HIF-dependent receptor families, such as VEGFR-1, -2 and -3 [2].